Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.
EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System
EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease
EP: 3.Genetic Aspects of Alzheimer Disease
EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease
EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease
EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing
EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease
Now Viewing
EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
EP: 9.Clinical Decision-Making for Alzheimer Disease Management
EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease
EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease
EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Video content above is prompted by the following question(s):
- What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
- Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
- Lecanemab approved by the FDA in 2023
Related Videos
Related Content
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Article
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
